Current and next generation influenza vaccines: Formulation and production strategies.

Eur J Pharm Biopharm

Intravacc (Institute for Translational Vaccinology), Bilthoven, The Netherlands; Division of Drug Delivery and Technology, Leiden Academic Centre for Drug Research, Leiden University, The Netherlands.

Published: August 2015

Vaccination is the most effective method to prevent influenza infection. However, current influenza vaccines have several limitations. Relatively long production times, limited vaccine capacity, moderate efficacy in certain populations and lack of cross-reactivity are important issues that need to be addressed. We give an overview of the current status and novel developments in the landscape of influenza vaccines from an interdisciplinary point of view. The feasibility of novel vaccine concepts not only depends on immunological or clinical outcomes, but also depends on biotechnological aspects, such as formulation and production methods, which are frequently overlooked. Furthermore, the next generation of influenza vaccines is addressed, which hopefully will bring cross-reactive influenza vaccines. These developments indicate that an exciting future lies ahead in the influenza vaccine field.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejpb.2015.05.023DOI Listing

Publication Analysis

Top Keywords

influenza vaccines
20
generation influenza
8
formulation production
8
influenza
7
vaccines
5
current generation
4
vaccines formulation
4
production strategies
4
strategies vaccination
4
vaccination effective
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!